As a monovalent cation channel, the transient receptor potential melastatin 4 (TRPM4) channel is a unique member of the transient receptor potential family. Abnormal TRPM4 activity has been identified in various neurologic disorders, such as stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, amyotrophic lateral sclerosis, pathologic pain, and epilepsy. Following brain hypoxia/ischemia and inflammation, TRPM4 up-regulation and enhanced activity contribute to the cell death of neurons, vascular endothelial cells, and astrocytes. Enhanced ionic influx via TRPM4 leads to cell volume increase and oncosis. Depolarization of membrane potential following TRPM4 activation and interaction between TRPM4 and N-methyl-d-aspartate receptors exacerbate excitotoxicity during hypoxia. Importantly, TRPM4 expression and activity remain low in healthy neurons, making it an ideal drug target. Current approaches to inhibit or modulate the TRPM4 channel have various limitations that hamper the interpretation of TRPM4 physiology in the nervous system and potentially hinder their translation into therapy. In this review, we discuss the pathophysiologic roles of TRPM4 and the different inhibitors that modulate TRPM4 activity for potential treatment of neurologic diseases.
AbrielHSyamNSottasVAmarouchMYRougierJS. 2012. TRPM4 channels in the cardiovascular system: physiology, pathophysiology, and pharmacology. Biochem Pharmacol84:873–81.
ArullampalamPPretiBRoss-KaschitzaDLochnerMRougierJSAbrielH.2021. Species-specific effects of cation channel TRPM4 small-molecule inhibitors. Front Pharmaco12:712354.
4.
BarbetGDemionMMouraICSerafiniNLegerTVrtovsnikF, and others. 2008. The calcium-activated nonselective cation channel TRPM4 is essential for the migration but not the maturation of dendritic cells. Nat Immunol9:1148–56.
BianchiBSmithPAAbrielH.2018. The ion channel TRPM4 in murine experimental autoimmune encephalomyelitis and in a model of glutamate-induced neuronal degeneration. Mol Brain11:41.
7.
BorgstromAPeineltC.2021. Small molecular inhibitors block TRPM4 currents in prostate cancer cells, with limited impact on cancer hallmark functions. J Mol Biol433:166665.
8.
BramlettHMDietrichWD. 2007. Progressive damage after brain and spinal cord injury: pathomechanisms and treatment strategies. Prog Brain Res161:125–41.
CaffesNKurlandDBGerzanichVSimardJM. 2015. Glibenclamide for the treatment of ischemic and hemorrhagic stroke. Int J Mol Sci16:4973–84.
11.
CakirMSacmaciHSabah-OzcanS.2021. Selected transient receptor potential channel genes’ expression in peripheral blood mononuclear cells of multiple sclerosis. Hum Exp Toxicol40: S406–13.
12.
CatapanoJSKoesterSWBondKMSrinivasanVMFarhadiDSRumallaK, and others. 2023. Outcomes in patients with aneurysmal subarachnoid hemorrhage receiving sulfonylureas: a propensity-adjusted analysis. World Neurosurg176:e400–7.
13.
ChangHYangJWangQZhaoJZhuR.2022. Role of N6-methyladenosine modification in pathogenesis of ischemic stroke. Expert Rev Mol Diagn22:295–303.
14.
ChenBGaoYWeiSLowSWNgGYuD, and others. 2019. TRPM4-specific blocking antibody attenuates reperfusion injury in a rat model of stroke. Pflugers Arch471:1455–66.
ChenBWeiSLowSWPooreCPLeeATNiliusB, and others. 2023. TRPM4 blocking antibody protects cerebral vasculature in delayed stroke reperfusion. Biomedicines11:1480.
17.
ChenMDongYSimardJM. 2003. Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain. J Neurosci23:8568–77.
18.
ChenMSimardJM. 2001. Cell swelling and a nonselective cation channel regulated by internal Ca2+ and ATP in native reactive astrocytes from adult rat brain. J Neurosci21:6512–21.
19.
ChenXLiuKLinZHuangKPanS.2020. Knockout of transient receptor potential melastatin 4 channel mitigates cerebral edema and neuronal injury after status epilepticus in mice. J Neuropathol Exp Neurol79:1354–64.
ChengHBeckALaunayPGrossSAStokesAJKinetJP, and others. 2007. TRPM4 controls insulin secretion in pancreatic beta-cells. Cell Calcium41:51–61.
22.
ChoCHKimELeeYSYarishkinOYooJCParkJY, and others. 2014. Depletion of 14-3-3gamma reduces the surface expression of transient receptor potential melastatin 4b (TRPM4b) channels and attenuates TRPM4b-mediated glutamate-induced neuronal cell death. Mol Brain7:52.
23.
ChoEParkJY. 2020. Emerging roles of 14-3-3gamma in the brain disorder. BMB Rep53:500–11.
24.
da CostaBBSWindlinICKoterbaEYamakiVNRabeloNN, and others. 2019. Glibenclamide in aneurysmatic subarachnoid hemorrhage (GASH): study protocol for a randomized controlled trial. Trials20(1):413.
25.
DasMMohapatraSMohapatraSS. 2012. New perspectives on central and peripheral immune responses to acute traumatic brain injury. J Neuroinflammation9:236.
26.
DebonoMWLe GuernJCantonTDobleAPradierL.1993. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol235:283–9.
27.
DienesCKovacsZMHezsoTAlmassyJMagyarJBanyaszT, and others. 2021. Pharmacological modulation and (patho)physiological roles of TRPM4 channel—part 2: TRPM4 in health and disease. Pharmaceuticals (Basel)15:40.
28.
EarleySWaldronBJBraydenJE. 2004. Critical role for transient receptor potential channel TRPM4 in myogenic constriction of cerebral arteries. Circ Res95:922–9.
29.
EcheverriaCMontorfanoICabello-VerrugioCArmisenRVarelaDSimonF.2015. Suppression of transient receptor potential melastatin 4 expression promotes conversion of endothelial cells into fibroblasts via transforming growth factor/activin receptor-like kinase 5 pathway. J Hypertens33:981–92.
30.
FavillaCGMullenMTAliMHigginsPKasnerSE; Virtual International Stroke Trials Archive (VISTA) Collaboration. 2011. Sulfonylurea use before stroke does not influence outcome. Stroke42:710–5.
31.
FeareyBCBinkleLMenschingDSchulzeCLohrCFrieseMA, and others. 2022. A glibenclamide-sensitive TRPM4-mediated component of CA1 excitatory postsynaptic potentials appears in experimental autoimmune encephalomyelitis. Sci Rep12:6000.
32.
FengXZhangTWangNQuXQiMZhaoH, and others. 2024. Safety and efficacy of glibenclamide on cerebral oedema following aneurysmal subarachnoid haemorrhage: a randomised, double-blind, placebo-controlled clinical trial. Stroke Vasc Neurol9:530–40.
33.
GaoYLiaoP.2019. TRPM4 channel and cancer. Cancer Lett454:66–9.
34.
GarlandCJSmirnovSVBagherPLimCSHuangCYMitchellR, and others. 2015. TRPM4 inhibitor 9-phenanthrol activates endothelial cell intermediate conductance calcium-activated potassium channels in rat isolated mesenteric artery. Br J Pharmacol172:1114–23.
35.
GerzanichVMakarTKGudaPRKwonMSStokumJAWooSK, and others. 2017. Salutary effects of glibenclamide during the chronic phase of murine experimental autoimmune encephalomyelitis. J Neuroinflammation14:177.
36.
GerzanichVStokumJAIvanovaSWooSKTsymbalyukOSharmaA, and others. 2019. Sulfonylurea receptor 1, transient receptor potential cation channel subfamily M member 4, and KIR6.2: role in hemorrhagic progression of contusion. J Neurotrauma36:1060–79.
37.
GerzanichVWooSKVennekensRTsymbalyukOIvanovaSIvanovA, and others. 2009. De novo expression of Trpm4 initiates secondary hemorrhage in spinal cord injury. Nat Med15:185–91.
38.
GonzalesALAmbergGCEarleyS.2010. Ca2+ release from the sarcoplasmic reticulum is required for sustained TRPM4 activity in cerebral artery smooth muscle cells. Am J Physiol Cell Physiol299:C279–88.
39.
GoutmanSAHardimanOAl-ChalabiAChioASavelieffMGKiernanMCFeldmanEL. 2022. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol21:465–79.
40.
GrandTDemionMNorezCMetteyYLaunayPBecqF, and others. 2008. 9-Phenanthrol inhibits human TRPM4 but not TRPM5 cationic channels. Br J Pharmacol153:1697–705.
GuinamardRSimardCDel NegroC.2013. Flufenamic acid as an ion channel modulator. Pharmacol Ther138:272–84.
43.
HazalinNLiaoPHassanZ.2020. TRPM4 inhibition improves spatial memory impairment and hippocampal long-term potentiation deficit in chronic cerebral hypoperfused rats. Behav Brain Res393:112781.
44.
HeslinMThonJThauLRanaAThenRJovinT, and others. 2021. Safety of off-label oral glyburide in malignant hemispheric infarctions: a single-center quality improvement study. Stroke52:AP280.
45.
HorsdalHTMehnertFRungbyJJohnsenSP. 2012. Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study. J Stroke Cerebrovasc Dis21:717–25.
46.
HuangKHuYWuYJiZWangS, and others. 2019. Exploratory analysis of oral glibenclamide in acute ischemic stroke. Acta Neurol Scand140:212-18.
47.
HuangKZhaoXZhaoYYangGZhouSYangZ, and others. 2023. Safety and efficacy of glibenclamide combined with rtPA in acute cerebral ischemia with occlusion/stenosis of anterior circulation (SE-GRACE): a randomized, double-blind, placebo-controlled trial. eClinicalMedicine65:102305.
48.
JhaRMDesaiSMZusmanBEKoleckTAPuccioAMOkonkwoDO, and others. 2019. Downstream TRPM4 polymorphisms are associated with intracranial hypertension and statistically interact with ABCC8 polymorphisms in a prospective cohort of severe traumatic brain injury. J Neurotrauma36:1804–17.
49.
JhaRMElmerJZusmanBEDesaiSPuccioAMOkonkwoDO, and others. 2018. Intracranial pressure trajectories: a novel approach to informing severe traumatic brain injury phenotypes. Crit Care Med46:1792–802.
50.
JhaRMPuccioAMChouSHChangCHWallischJSMolyneauxBJ, and others. 2017. Sulfonylurea receptor-1: a novel biomarker for cerebral edema in severe traumatic brain injury. Crit Care Med45:e255–64.
51.
JhaRMSimardJM. 2023. Glibenclamide for brain contusions: contextualizing a promising clinical trial design that leverages an imaging-based TBI endotype. Neurotherapeutics20:1472–81.
52.
JhaRMZusmanBEPuccioAMOkonkwoDOPeaseMDesaiSM, and others. 2021. Genetic variants associated with intraparenchymal hemorrhage progression after traumatic brain injury. JAMA Netw Open4: e2116839.
53.
JiangBLiLChenQTaoYYangLZhangB, and others. 2017. Role of glibenclamide in brain injury after intracerebral hemorrhage. Transl Stroke Res8:183–93.
54.
JiangXLiuBNieZDuanLXiongQJinZ, and others. 2021. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther6:74.
55.
KahleKTSimardJMStaleyKJNahedBVJonesPSSunD.2009. Molecular mechanisms of ischemic cerebral edema: role of electroneutral ion transport. Physiology (Bethesda)24:257–65.
56.
KhaliliHDerakhshanNNiakanAGhaffarpasandFSalehiMEshraghianH, and others. 2017. Effects of oral glibenclamide on brain contusion volume and functional outcome of patients with moderate and severe traumatic brain injuries: a randomized double-blind placebo-controlled clinical trial. World Neurosurg101:130–6.
57.
KhannaAKahleKTWalcottBPGerzanichVSimardJM. 2014. Disruption of ion homeostasis in the neurogliovascular unit underlies the pathogenesis of ischemic cerebral edema. Transl Stroke Res5:3–16.
58.
KhannaAWalcottBPKahleKTSimardJM. 2014. Effect of glibenclamide on the prevention of secondary brain injury following ischemic stroke in humans. Neurosurg Focus36: E11.
59.
KimYSKangEMakinoYParkSShinJHSongH, and others. 2013. Characterizing the conductance underlying depolarization-induced slow current in cerebellar Purkinje cells. J Neurophysiol109:1174–81.
60.
KimberlyWTBatteyTWPhamLWuOYooAJFurieKL, and others. 2014. Glyburide is associated with attenuated vasogenic edema in stroke patients. Neurocrit Care20:193–201.
61.
KimberlyWTBeversMBvon KummerRDemchukAMRomeroJMElmJJ, and others. 2018. Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP trial. Neurology91:e2163–9.
62.
KovacsZMDienesCHezsoTAlmassyJMagyarJBanyaszT, and others. 2022. Pharmacological modulation and (patho)physiological roles of TRPM4 channel—part 1: modulation of TRPM4. Pharmaceuticals (Basel)15:81.
63.
KrockerJDCottonMESchrinerJBOsbornBKTalankerMMWangYW, and others. 2023. Influence of TRPM4 rs8104571 genotype on intracranial pressure and outcomes in African Americans with traumatic brain injury. Sci Rep13:5815.
64.
KungTFCWilkinsonCMLiddleLJColbourneF. 2023. A systematic review and meta-analysis on the efficacy of glibenclamide in animal models of intracerebral hemorrhage. PLoS One18:e0292033.
65.
KunteHBuschMATrostdorfKVollnbergBHarmsLMehtaRI, and others. 2012. Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas. Ann Neurol72:799–806.
66.
KurlandDBGerzanichVKarimyJKWooSKVennekensRFreichelM, and others. 2016. The Sur1-Trpm4 channel regulates NOS2 transcription in TLR4-activated microglia. J Neuroinflammation13:130.
67.
LaunayPChengHSrivatsanSPennerRFleigAKinetJP. 2004. TRPM4 regulates calcium oscillations after T cell activation. Science306:1374–77.
68.
LeeJYChoiHYNaWHJuBGYuneTY. 2014. Ghrelin inhibits BSCB disruption/hemorrhage by attenuating MMP-9 and SUR1/TrpM4 expression and activation after spinal cord injury. Biochim Biophys Acta1842:2403–12.
69.
LeeJYChoiHYParkCSJuBGYuneTY. 2018. Mithramycin A improves functional recovery by inhibiting BSCB disruption and hemorrhage after spinal cord injury. J Neurotrauma35:508–20.
70.
Leiva-SalcedoERiquelmeDCerdaOStutzinA.2017. TRPM4 activation by chemically- and oxygen deprivation-induced ischemia and reperfusion triggers neuronal death. Channels (Austin)11:624–35.
71.
Lezama-GarcíaKMota-RojasDPereiraAMFMartinez-BurnesJGhezziMDominguezA, and others. 2022. Transient receptor potential (TRP) and thermoregulation in animals: structural biology and neurophysiological aspects. Animals (Basel)12:106.
72.
LimaRMonteiroASalgadoAJMonteiroSSilvaNA. 2022. Pathophysiology and therapeutic approaches for spinal cord injury. Int J Mol Sci23:13833.
73.
LinQZhouDMaJZhaoJChenGWuL, and others. 2024. Efficacy and safety of early treatment with glibenclamide in patients with aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Neurocrit Care41:828–39.
74.
LinZHuangHGuYHuangKHuYJiZ, and others. 2017. Glibenclamide ameliorates cerebral edema and improves outcomes in a rat model of status epilepticus. Neuropharmacology121:1–11.
75.
LiuRWangHXuBChenWTurlovaEDongN, and others 2016. Cerebrovascular safety of sulfonylureas: the role of KATP channels in neuroprotection and the risk of stroke in patients with type 2 diabetes. Diabetes65:2795–809.
76.
LohKPNgGYuCYFhuCKYuDVennekensR, and others. 2014. TRPM4 inhibition promotes angiogenesis after ischemic stroke. Pflugers Arch466:563–76.
77.
LohKYWangZLiaoP.2019. Oncotic cell death in stroke. Rev Physiol Biochem Pharmacol176:37–64.
78.
LowSWGaoYWeiSChenBNiliusBLiaoP.2021. Development and characterization of a monoclonal antibody blocking human TRPM4 channel. Sci Rep11:10411.
79.
LuuWBjorkJSaloEEntenmannNJurgensonTFisherC, and others. 2019. Modulation of SUR1 K(ATP) channel subunit activity in the peripheral nervous system reduces mechanical hyperalgesia after nerve injury in mice. Int J Mol Sci20.
80.
MaPHuangNTangJZhouZXuJChenY, and others. 2023. The TRPM4 channel inhibitor 9-phenanthrol alleviates cerebral edema after traumatic brain injury in rats. Front Pharmacol14:1098228.
81.
MakarTKGerzanichVNimmagaddaVKJainRLamKMubarizF, and others. 2015. Silencing of Abcc8 or inhibition of newly upregulated Sur1-Trpm4 reduce inflammation and disease progression in experimental autoimmune encephalomyelitis. J Neuroinflammation12:210.
82.
MalhotraSCastillóJNegrottoLMerino-ZamoranoCMontanerJVidal-JordanaA, and others. 2013. TRPM4 mRNA expression levels in peripheral blood mononuclear cells from multiple sclerosis patients. J Neuroimmunol261:146–8.
83.
Martinez-ValverdeTVidal-JorgeMMartinez-SaezECastroLArikanFCorderoE, and others. 2015. Sulfonylurea receptor 1 in humans with post-traumatic brain contusions. J Neurotrauma32:1478–87.
MatharIVennekensRMeissnerMKeesFVan der MierenGCamacho LondonoJE, and others. 2010. Increased catecholamine secretion contributes to hypertension in TRPM4-deficient mice. J Clin Invest120:3267–79.
86.
MehtaRITosunCIvanovaSTsymbalyukNFamakinBMKwonMS, and others. 2015. Sur1-Trpm4 cation channel expression in human cerebral infarcts. J Neuropathol Exp Neurol74:835–49.
87.
MenigozAAhmedTSabanovVPhilippaertKPintoSKerselaersS, and others. 2016. TRPM4-dependent post-synaptic depolarization is essential for the induction of NMDA receptor-dependent LTP in CA1 hippocampal neurons. Pflugers Arch468:593–607.
88.
MinnemaAJMehtaABolingWWSchwabJSimardJMFarhadiHF. 2019. SCING–spinal cord injury neuroprotection with glyburide: a pilot, open-label, multicentre, prospective evaluation of oral glyburide in patients with acute traumatic spinal cord injury in the USA. BMJ Open9:e031329.
89.
MundruczLKecskesAHenn-MikeNKoborPBuzasPVennekensR, and others. 2023. TRPM4 regulates hilar mossy cell loss in temporal lobe epilepsy. BMC Biol21:96.
90.
NiliusBPrenenJDroogmansGVoetsTVennekensRFreichelM, and others. 2003. Voltage dependence of the Ca2+-activated cation channel TRPM4. J Biol Chem278:30813–20.
91.
NiliusBPrenenJJanssensAOwsianikGWangCZhuMX, and others. 2005. The selectivity filter of the cation channel TRPM4. J Biol Chem280:22899–906.
92.
NiliusBPrenenJVoetsTDroogmansG.2004. Intracellular nucleotides and polyamines inhibit the Ca2+-activated cation channel TRPM4b. Pflugers Arch448:70–5.
93.
OzhathilLCDelalandeCBianchiBNemethGKappelSThometU, and others. 2018. Identification of potent and selective small molecule inhibitors of the cation channel TRPM4. Br J Pharmacol175:2504–19.
94.
PapiriGD’AndreamatteoGCacchiòGAliaSSilvestriniMPaciC, and others. 2023. Multiple sclerosis: inflammatory and neuroglial aspects. Curr Issues Mol Biol45:1443–70.
95.
PatelADGerzanichVGengZSimardJM. 2010. Glibenclamide reduces hippocampal injury and preserves rapid spatial learning in a model of traumatic brain injury. J Neuropathol Exp Neurol69:1177–90.
96.
PicardoMCDSugimuraYKDorstKEKallurkarPSAkinsVTMaX, and others. 2019. Trpm4 ion channels in pre-Botzinger complex interneurons are essential for breathing motor pattern but not rhythm. PLoS Biol17:e2006094.
97.
PooreCPHazalin Namn, WeiSLowSWChenBNiliusB, and others. 2024. TRPM4 blocking antibody reduces neuronal excitotoxicity by specifically inhibiting glutamate-induced calcium influx under chronic hypoxia. Neurobiol Dis191:106408.
98.
PooreCPWeiSChenBLowSWTanJSQLeeAT, and others. 2024. In vivo evaluation of monoclonal antibody M4M using a humanised rat model of stroke demonstrates attenuation of reperfusion injury via blocking human TRPM4 channel. J Drug Target32:413–22.
99.
ReadingSABraydenJE. 2007. Central role of TRPM4 channels in cerebral blood flow regulation. Stroke38:2322–8.
100.
RiquelmeDPeraltaFANavarroFDMorenoCLeiva-SalcedoE.2021. I(CAN) (TRPM4) contributes to the intrinsic excitability of prefrontal cortex layer 2/3 pyramidal neurons. Int J Mol Sci22:5268.
101.
RobinsonAPHarpCTNoronhaAMillerSD. 2014. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol122:173–89.
102.
Sala-RabanalMWangSNicholsCG. 2012. On potential interactions between non-selective cation channel TRPM4 and sulfonylurea receptor SUR1. J Biol Chem287:8746–56.
103.
SarmientoDMontorfanoICerdaOCaceresMBecerraACabello-VerrugioC, and others. 2015. Increases in reactive oxygen species enhance vascular endothelial cell migration through a mechanism dependent on the transient receptor potential melastatin 4 ion channel. Microvasc Res98:187–96.
104.
SchattlingBSteinbachKThiesEKruseMMenigozAUferF, and others. 2012. TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med18:1805–11.
105.
SenguptaSWestKOSanghviSLaliotisGAgostoLMLynchKW, and others. 2021. PRMT5 promotes symmetric dimethylation of RNA processing proteins and modulates activated T cell alternative splicing and Ca(2+)/NFAT signaling. Immunohorizons5:884–97.
106.
ShethKNElmJJMolyneauxBJHinsonHBeslowLASzeGK, and others. 2016. Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol15:1160–9.
107.
ShethKNKimberlyWTElmJJKentTAMandavaPYooAJ, and others. 2014. Pilot study of intravenous glyburide in patients with a large ischemic stroke. Stroke45:281–3.
108.
ShethKNKimberlyWTElmJJKentTAYooAJThomallaG, and others 2014. Exploratory analysis of glyburide as a novel therapy for preventing brain swelling. Neurocrit Care21:43–51.
109.
ShethKNPetersenNHCheungKElmJJHinsonHEMolyneauxBJ, and others. 2018. Long-term outcomes in patients aged ≤70 years with intravenous glyburide from the phase II GAMES-RP study of large hemispheric infarction: an exploratory analysis. Stroke49:1457–63.
110.
ShethKNSimardJMElmJKronenbergGKunteHKimberlyWT. 2016. Human data supporting glyburide in ischemic stroke. Acta Neurochir Suppl121:13–8.
111.
SimardJMChenMTarasovKVBhattaSIvanovaSMelnitchenkoL, and others. 2006. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med12:433–40.
112.
SimardJMKilbourneMTsymbalyukOTosunCCaridiJIvanovaS, and others. 2009. Key role of sulfonylurea receptor 1 in progressive secondary hemorrhage after brain contusion. J Neurotrauma26:2257–67.
113.
SimardJMPopovichPGTsymbalyukOCaridiJGullapalliRPKilbourneMJ, and others. 2013. MRI evidence that glibenclamide reduces acute lesion expansion in a rat model of spinal cord injury. Spinal Cord51:823–7.
114.
SimardJMTsymbalyukNTsymbalyukOIvanovaSYurovskyVGerzanichV.2010. Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke. Stroke41:531–7.
SimardJMTsymbalyukOKeledjianKIvanovAIvanovaSGerzanichV.2012. Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury. Exp Neurol233:566–74.
SimardJMWooSKTsymbalyukOVoloshynOYurovskyVIvanovaS, and others. 2012. Glibenclamide-10-h treatment window in a clinically relevant model of stroke. Transl Stroke Res3:286–95.
119.
SimonFLeiva-SalcedoEArmisenRRiverosACerdaOVarelaD, and others. 2010. Hydrogen peroxide removes TRPM4 current desensitization conferring increased vulnerability to necrotic cell death. J Biol Chem285:37150–8.
120.
SinghATrevickS.2016. The epidemiology of global epilepsy. Neurol Clin34:837–47.
121.
SongJHHuangCSNagataKYehJZNarahashiT.1997. Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther282:707–14.
122.
StallmeyerBZumhagenSDenjoyIDuthoitGHébertJLFerrerX, and others. 2012. Mutational spectrum in the Ca(2+)–activated cation channel gene TRPM4 in patients with cardiac conductance disturbances. Hum Mutat33:109–17.
123.
StokumJAKwonMSWooSKTsymbalyukOVennekensRGerzanichV, and others. 2018. SUR1-TRPM4 and AQP4 form a heteromultimeric complex that amplifies ion/water osmotic coupling and drives astrocyte swelling. Glia66:108–25.
124.
StokumJAShimBNegoitaSTsymbalyukNTsymbalyukOIvanovaS, and others. 2023. Cation flux through SUR1-TRPM4 and NCX1 in astrocyte endfeet induces water influx through AQP4 and brain swelling after ischemic stroke. Sci Signal16:eadd6364.
125.
TosunCKurlandDBMehtaRCastellaniRJdeJongJLKwonMS, and others. 2013. Inhibition of the Sur1-Trpm4 channel reduces neuroinflammation and cognitive impairment in subarachnoid hemorrhage. Stroke44(12):3522–8.
126.
TranTDZolochevskaOFigueiredoMLWangHYangLJGimbleJM, and others. 2014. Histamine-induced Ca2+ signalling is mediated by TRPM4 channels in human adipose-derived stem cells. Biochem J463:123–34.
127.
TsymbalyukOGerzanichVMumtazAAndhavarapuSIvanovaSMakarTK, and others. 2021. SUR1, newly expressed in astrocytes, mediates neuropathic pain in a mouse model of peripheral nerve injury. Mol Pain17:17448069211006603.
128.
UllrichNDVoetsTPrenenJVennekensRTalaveraKDroogmansG, and others. 2005. Comparison of functional properties of the Ca2+-activated cation channels TRPM4 and TRPM5 from mice. Cell Calcium37:267–78.
129.
VennekensROlaussonJMeissnerMBlochWMatharIPhilippSE, and others. 2007. Increased IgE-dependent mast cell activation and anaphylactic responses in mice lacking the calcium-activated nonselective cation channel TRPM4. Nat Immunol8:312–20.
130.
VigilanteNPatelKOakSButlerMThonJMSieglerJE. 2023. Outcomes following off-label glyburide in large hemispheric infarction: a single-center experience. Stroke54:ATP106.
131.
VorasayanPBeversMBBeslowLASzeGMolyneauxBJHinsonHE, and others. 2019. Intravenous glibenclamide reduces lesional water uptake in large hemispheric infarction. Stroke50:3021–7.
132.
WeiSBehnJPooreCPLowSWNiliusBFanH, and others. 2022. Binding epitope for recognition of human TRPM4 channel by monoclonal antibody M4M. Sci Rep12:19562.
133.
WeiSChenBLowSWPooreCPGaoYNiliusB, and others. 2023. SLC26A11 inhibition reduces oncotic neuronal death and attenuates stroke reperfusion injury. Mol Neurobiol60:5931–43.
134.
WeiSLowSWPooreCPChenBGaoYNiliusB, and others. 2020. Comparison of anti-oncotic effect of TRPM4 blocking antibody in neuron, astrocyte and vascular endothelial cell under hypoxia. Front Cell Dev Biol8:562584.
135.
WeihMAmbergerNWegenerSDirnaglUReuterTEinhäuplK.2001. Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes. Stroke32:2029–32.
136.
WooSKKwonMSIvanovAGerzanichVSimardJM, and others. 2013. The sulfonylurea receptor 1 (Sur1)–transient receptor potential melastatin 4 (Trpm4) channel. J Biol Chem288:3655–67.
YanJBengtsonCPBuchthalBHagenstonAMBadingH.2020. Coupling of NMDA receptors and TRPM4 guides discovery of unconventional neuroprotectants. Science370:eaay3302.
139.
YanJWangYMHellwigABadingH.2024. TwinF interface inhibitor FP802 stops loss of motor neurons and mitigates disease progression in a mouse model of ALS. Cell Rep Med5:101413.
140.
YuFHubrackSRaynaudCMElmiAMackehRAgrebiN, and others. 2024. Loss of the TRPM4 channel in humans causes immune dysregulation with defective monocyte migration. J Allergy Clin Immunol. 154(3):792–806.
141.
ZafardoostPGhasemiAASalehpourFPirotiCZiaeiiE.2016. Evaluation of the effect of glibenclamide in patients with diffuse axonal injury due to moderate to severe head trauma. Trauma21:5.
142.
ZhangLLiCHeYKuangCQiuXGuL, and others. 2023. TRPM4 drives cerebral edema by switching to alternative splicing isoform after experimental traumatic brain injury. J Neurotrauma40:1779–95.
143.
ZhangMMaYYeXZhangNPanLWangB.2023. TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases. Sig Transduct Target Ther8:261.
144.
ZhaoJSongCLiDYangXYuLWangK, and others. 2022. Efficacy and safety of glibenclamide therapy after intracerebral haemorrhage (GATE-ICH): a multicentre, prospective, randomised, controlled, open-label, blinded-endpoint, phase 2 clinical trial. E Clinical Medicine53:101666.
145.
ZhaoKWenRWangXPeiLYangYShangY, and others. 2013. EPAC inhibition of SUR1 receptor increases glutamate release and seizure vulnerability. J Neurosci33:8861–5.
146.
ZweckbergerKHackenbergKJungCSHertleDNKieningKLUnterbergAW, and others. 2014. Glibenclamide reduces secondary brain damage after experimental traumatic brain injury. Neurosci272:199–206.
